profit from every $100 of sales.
$0$100
Chemomab Therapeutics
$1.53+9.29% today
-40.0% in 1 year
1-year low $1.001-year high $2.83
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Chemomab Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$9.00 million of profit last year.
SalesProfit
Chemomab Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Chemomab Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Chemomab Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -29 | -25 | -15 | -10 | |
| -28 | -25 | -15 | -9 | |
| -28 | -24 | -14 | -9 | |
| -9.68 | -8.24 | -3.44 | -1.44 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 43 | 22 | 17 | 14 |
| Cash | 14 | 9 | 6 | 8 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 7 | 5 | 3 | 1 |
| 36 | 17 | 14 | 12 | |
| 3 | 3 | 4 | 6 | |
| -61.9% | -115.7% | -84.0% | -61.3% | |
| -76.3% | -142.5% | -103.0% | -72.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -20 | -24 | -15 | -11 | |
| 0 | 0 | – | 0 | |
| -20 | -24 | -15 | -11 | |
| Dividends paid | – | – | – | – |
| 1 | 0 | 0 | – | |
| 3 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 1.1×
- –
- –
- –
- -91.1%
- -73.6%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -77.7%
- -81.9%
- -82.5%
- -65.2%
- -77.7%
- –
Growth
- –
- –
- +27.4%
- –
- +25.2%
Financial health
- -0.8×
- 0.00
- 0.0%
- –
- 9.08
- 9.08
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 946
Bottom 21%of 871
Bottom 1%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.22 | -0.04 | −450.0% |
| Mar 19, 2026 | -0.24 | -0.20 | −20.0% |
| Nov 13, 2025 | -0.80 | -0.20 | −300.0% |
| Aug 14, 2025 | -0.36 | -0.80 | +55.0% |
| May 15, 2025 | -0.14 | -0.20 | +30.0% |
| Mar 3, 2025 | -0.16 | -0.20 | +20.0% |
| Nov 14, 2024 | -0.20 | -0.20 | +0.0% |
| Aug 21, 2024 | -0.26 | -0.20 | −30.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
65Pass
Philip Fisher
35No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
34No pass
Questions about Chemomab Therapeutics
Is Chemomab Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Chemomab Therapeutics AI analysis
What does Chemomab Therapeutics do?
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. It is in Biotechnology.
Does Chemomab Therapeutics pay a dividend?
No. Chemomab Therapeutics does not pay a dividend at the moment.
Is Chemomab Therapeutics stock halal?
No. Chemomab Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 61% of its market value, at or above the 33% limit. How we check
How has Chemomab Therapeutics stock done over the past year?
Down 40.0% over the past twelve months, to $1.53. It traded between $1.00 and $2.83 and is 45.9% below its high.
Who are Chemomab Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Chemomab Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.